Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.: Journal of the American Society of Nephrology : JASN

Harm H. H. Feringa; Stefanos E. Karagiannis; Michel Chonchol; Radosav Vidakovic; Peter G. Noordzij; Abdou Elhendy; Ron T. van Domburg; Gijs Welten; Olaf Schouten; Jeroen J. Bax; Tomas Berl; Don Poldermans

doi:10.1681/ASN.2006080887

Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN

Harm H. H. Feringa
, Stefanos E. Karagiannis
, Michel Chonchol
, Radosav Vidakovic
, Peter G. Noordzij
, Abdou Elhendy
, Ron T. van Domburg
, Gijs Welten
, Olaf Schouten
, Jeroen J. Bax
, Tomas Berl
, Don Poldermans

Anesthesiology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-converting enzyme inhibitors (ACEI) are associated with improved renal and cardiovascular outcome in patients with PAD. In a prospective observational cohort study of 1940 consecutive patients with PAD, ABI was measured and chronic statin and ACEI therapy was noted at baseline. Serial creatinine concentrations were obtained at baseline, 6 mo, and every year after enrollment. End points were ESRD, all-cause mortality, and cardiac events during a median follow-up period of 8 yr. Baseline estimated GFR

Original language	English
Pages (from-to)	1872-1879
Number of pages	8
Journal	Journal of the American Society of Nephrology
Volume	18
Issue number	6
DOIs	https://doi.org/10.1681/ASN.2006080887
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aged
Female
Humans
Male
Middle Aged
Risk Factors
Prospective Studies
Kaplan-Meier Estimate
Multivariate Analysis
Follow-Up Studies
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Disease Progression
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Kidney Failure, Chronic/*mortality/physiopathology
Peripheral Vascular Diseases/*drug therapy/*mortality
Prevalence

Access to Document

10.1681/ASN.2006080887

Fingerprint

Dive into the research topics of 'Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN'. Together they form a unique fingerprint.

Risk management of complex surgical patients
Noordzij, P. (Principal investigator)
20/10/2010 → …
Project: Research

Cite this

Feringa, H. H. H., Karagiannis, S. E., Chonchol, M., Vidakovic, R., Noordzij, P. G., Elhendy, A., van Domburg, R. T., Welten, G., Schouten, O., Bax, J. J., Berl, T., & Poldermans, D. (2007). Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN. Journal of the American Society of Nephrology, 18(6), 1872-1879. https://doi.org/10.1681/ASN.2006080887

Feringa, Harm H. H. ; Karagiannis, Stefanos E. ; Chonchol, Michel et al. / Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN. In: Journal of the American Society of Nephrology. 2007 ; Vol. 18, No. 6. pp. 1872-1879.

@article{11d80810716a4539a757012c43476dd8,

title = "Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.: Journal of the American Society of Nephrology : JASN",

abstract = "Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-converting enzyme inhibitors (ACEI) are associated with improved renal and cardiovascular outcome in patients with PAD. In a prospective observational cohort study of 1940 consecutive patients with PAD, ABI was measured and chronic statin and ACEI therapy was noted at baseline. Serial creatinine concentrations were obtained at baseline, 6 mo, and every year after enrollment. End points were ESRD, all-cause mortality, and cardiac events during a median follow-up period of 8 yr. Baseline estimated GFR ",

keywords = "Aged, Female, Humans, Male, Middle Aged, Risk Factors, Prospective Studies, Kaplan-Meier Estimate, Multivariate Analysis, Follow-Up Studies, Angiotensin-Converting Enzyme Inhibitors/*therapeutic use, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use, Kidney Failure, Chronic/*mortality/physiopathology, Peripheral Vascular Diseases/*drug therapy/*mortality, Prevalence",

author = "Feringa, \{Harm H. H.\} and Karagiannis, \{Stefanos E.\} and Michel Chonchol and Radosav Vidakovic and Noordzij, \{Peter G.\} and Abdou Elhendy and \{van Domburg\}, \{Ron T.\} and Gijs Welten and Olaf Schouten and Bax, \{Jeroen J.\} and Tomas Berl and Don Poldermans",

year = "2007",

doi = "10.1681/ASN.2006080887",

language = "English",

volume = "18",

pages = "1872--1879",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "American Society of Nephrology",

number = "6",

}

Feringa, HHH, Karagiannis, SE, Chonchol, M, Vidakovic, R, Noordzij, PG, Elhendy, A, van Domburg, RT, Welten, G, Schouten, O, Bax, JJ, Berl, T & Poldermans, D 2007, 'Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN', Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1872-1879. https://doi.org/10.1681/ASN.2006080887

Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN. / Feringa, Harm H. H.; Karagiannis, Stefanos E.; Chonchol, Michel et al.
In: Journal of the American Society of Nephrology, Vol. 18, No. 6, 2007, p. 1872-1879.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.

T2 - Journal of the American Society of Nephrology : JASN

AU - Feringa, Harm H. H.

AU - Karagiannis, Stefanos E.

AU - Chonchol, Michel

AU - Vidakovic, Radosav

AU - Noordzij, Peter G.

AU - Elhendy, Abdou

AU - van Domburg, Ron T.

AU - Welten, Gijs

AU - Schouten, Olaf

AU - Bax, Jeroen J.

AU - Berl, Tomas

AU - Poldermans, Don

PY - 2007

Y1 - 2007

N2 - Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-converting enzyme inhibitors (ACEI) are associated with improved renal and cardiovascular outcome in patients with PAD. In a prospective observational cohort study of 1940 consecutive patients with PAD, ABI was measured and chronic statin and ACEI therapy was noted at baseline. Serial creatinine concentrations were obtained at baseline, 6 mo, and every year after enrollment. End points were ESRD, all-cause mortality, and cardiac events during a median follow-up period of 8 yr. Baseline estimated GFR

AB - Patients with peripheral arterial disease (PAD) are at increased risk for ESRD and cardiovascular events. The primary objective was to assess the association between ankle-brachial index (ABI) values and renal outcome. The secondary objective was to evaluate whether statins and angiotensin-converting enzyme inhibitors (ACEI) are associated with improved renal and cardiovascular outcome in patients with PAD. In a prospective observational cohort study of 1940 consecutive patients with PAD, ABI was measured and chronic statin and ACEI therapy was noted at baseline. Serial creatinine concentrations were obtained at baseline, 6 mo, and every year after enrollment. End points were ESRD, all-cause mortality, and cardiac events during a median follow-up period of 8 yr. Baseline estimated GFR

KW - Aged

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Risk Factors

KW - Prospective Studies

KW - Kaplan-Meier Estimate

KW - Multivariate Analysis

KW - Follow-Up Studies

KW - Angiotensin-Converting Enzyme Inhibitors/therapeutic use

KW - Disease Progression

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Kidney Failure, Chronic/mortality/physiopathology

KW - Peripheral Vascular Diseases/drug therapy/mortality

KW - Prevalence

U2 - 10.1681/ASN.2006080887

DO - 10.1681/ASN.2006080887

M3 - Article

SN - 1046-6673

VL - 18

SP - 1872

EP - 1879

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 6

ER -

Feringa HHH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. Journal of the American Society of Nephrology : JASN. Journal of the American Society of Nephrology. 2007;18(6):1872-1879. doi: 10.1681/ASN.2006080887